Bis-aryl sulfonamides

Abstract

Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

1 . A modulator of the formula (I) or a salt or N-oxide thereof: 
     
       
         
         
             
             
         
       
       L is —C(O)—, —S—, —S(O)— or —S(O)2-; 
       X represents from 1 to 5 substituents independently selected from the group consisting of halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, —CN, —NO2, —C(O)R1, —CO2R1, —C(O)NR1R2, —OR1, —OC(O)R1, —OC(O)NR1R2, —NO2, —NR3C(O)R1, —NR3C(O)NR1R2, —NR1R2, —NR3CO2R1, —NR3S(O)2R1, —SR1, —S(O)R1, —S(O)2R1, —S(O) 2 NR1R2, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
 substituted C 1-8  alkyl, substituted C 2-8  alkenyl, or substituted C 2-8  alkynyl may have from 1-5 substituents independently selected from the group consisting of halogen, —OH, —CN, —NO 2 , ═O, —OC(O)R 1 , —OR 1 , —C(O)R 1 , —C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —NR 2 C(O)R 1 , —NR 1 C(O)NR 2 R 3 , —CO 2 R 1 , —NR 1 R 2 , —NR 2 CO 2 R 1 , —SR 1 , —S(O)R 1 , —S(O) 2 R 1 , —S(O) 2 NR 1 R 2 , —NR 1 S(O) 2 R 2 , unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocyclyl; 
 substituted C 6-10  aryl, substituted 5- to 10-membered heteroaryl, or substituted 3- to 10-membered heterocyclyl, may have from 1-4 substituents independently selected from the group consisting of halogen, unsubstituted C 1-8  alkyl, unsubstituted C 1-8  haloalkyl, unsubstituted 4- to 7-membered heterocycle, —CN, —NO 2 , —OR 1 , ═O, —OC(O)R 1 , —CO 2 R 1 , —C(O)R 1 , —C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —NR 2 C(O)R 1 , —NR 1 C(O)NR 2 R 3 , —NR 1 R 2 , —NR 2 CO 2 R 1 , —SR 1 , —S(O)R 1 , —S(O) 2 R 1 , —S(O) 2 NR 1 R 2 , and —NR 1 S(O) 2 R, with the proviso that if X represents a heterocycle, suitable substituents preferably do not include another heterocycle; 
 R 1 , R 2  and R 3  are each independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, aryl-C 1-4  alkyl, aryloxy-C 1-4  alkyl, C 6-10  aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocycle, or where R 1  and R 2 , or R 3  and R 2 , or R 1  and R 3 , may together with the atom(s) to which they are attached, form an substituted or unsubstituted 5-, 6-, or 7-membered ring; 
 and where the aliphatic and aromatic portions of R 1 , R 2  and R 3  are optionally further substituted with from 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R n , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2  and —NR m S(O) 2 NHR n , where R m , R n , and R o  are each independently unsubstituted C 1-6  alkyl; 
 
       Y represents from 1 to 4 substituents, each independently selected from the group consisting of halogen, —CN, —NO 2 , —OR 4 , —C(O)R 4 , —CO2R4, —SR4, —S(O)R4, —S(O)2R4, and unsubstituted or substituted C1-4 alkyl;
 substituted C 1-4  alkyl may have from 1 to 3 substituents independently selected from the group consisting of halogen, —OR 4 , —CN, —NO 2 , ═O, —OC(O)R 4 , —CO 2 R 4 , —C(O)R 4 , —CONR 4 R 5 , —OC(O)NR 4 R 5 , —NR 4 C(O)R 5 , —NR 4 C(O)NR 5 R 6 , —NR 4 R 5 , —NR 4 CO 2 R 5 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 4 R 5 , and —NR 4 SO 2 R 5 ; 
 R 4 , R 5  and R 6  are each independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 6-10  aryl, and 5- to 10-membered heteroaryl; or where R 4  and R 5 , or R 6  and R 4  or R 5  and R 6 , together with the atom to which they are attached, form a substituted or unsubstituted 5-, 6- or 7-membered ring; 
 and the aliphatic and aromatic portions of R 4 , R 5 , and R 6  are optionally further substituted with from 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R n , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2  and —NR m S(O) 2 NHR n , where R m , R n , and R o  are each independently unsubstituted C 1-8  alkyl; and 
 
       Z represents from 0 to 5 substituents independently selected from the group consisting of halogen, unsubstituted or substituted C 1-8  alkyl, unsubstituted or substituted C 2-8  alkenyl, unsubstituted or substituted C 2-8  alkynyl, —CN, —NO 2 , —OR 7 , —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —CONR 7 R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 7 R 8 , —NR 7 CO 2 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —SO 2 NR 7 R 8 , —NR 7 SO 2 R 8 , unsubstituted or substituted C 6-10  aryl, unsubstituted or substituted 5- to 10-membered heteroaryl and unsubstituted or substituted 3- to 10-membered heterocyclyl;
 substituted C 1-8  alkyl, C 2-8  alkenyl and C 2-8  alkynyl substituents on Z may have from 1 to 5 substituents independently selected from the group consisting of halogen, —OR', —CN, —NO 2 , ═O, —CN, —NO 2 , —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —CONR 7 R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 7 R 8 , —NR 7 CO 2 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —SO 2 NR 7 R 8 , —NR 7 SO 2 R 8 , unsubstituted or substituted phenyl, unsubstituted or substituted 5- or 6-membered heteroaryl, or unsubstituted or substituted 4- to 7-membered heterocyclyl; 
 substituted aryl, heteroaryl and heterocyclyl substituents on Z may have from 1 to 5 substituents independently selected from the group consisting of halogen, —OR 7 , —CN, —NO 2 , ═O, —OC(O)R 7 , —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —CONR 7 R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 7 R 8 , —NR 7 CO 2 R 8 , —SR 7 , —SOR 7 , —SO 2 R 7 , —SO 2 NR 7 R 8 , —NR 7 SO 2 R 8 , unsubstituted 4- to 7-membered heterocyclyl, unsubstituted C 1-8  alkyl and unsubstituted C 1-8  haloalkyl; 
 R 7 , R 8  and R 9  are each independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 6-10  aryl, 5 to 10 membered heteroaryl and 3- to 10-membered heterocycle, or R 7  and R 8 , or R 8  and R 9 , or R 7  and R 9 , may together with the atom(s) to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring; and 
 the aliphatic and aromatic portions of R 7 , R 8  and R 9  are optionally further substituted with 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R n , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2  and —NR m S(O) 2 NHR n , where R m , R n , and R o  are each independently unsubstituted C 1-6  alkyl. 
 
     
   
   
       2 . A composition comprising a pharmaceutically acceptable carrier and a compound according to any of  claim 1 . 
   
   
       3 . A method for treating a CCR9-mediated condition or disease comprising administering to a subject a safe and effective amount of the compound according to any of  claim 1 . 
   
   
       4 . A method of modulating CCR9 function in a cell, comprising contacting the cell with a CCR9 modulating amount of the compound according to any of  claim 1 .